Holen Sie sich die Stockscreener-App
6.4199
0.90%
-0.0601
Schlusskurs vom Vortag:
$6.48
Offen:
$6.45
24-Stunden-Volumen:
43,208
Relative Volume:
0.01
Marktkapitalisierung:
$1.67B
Einnahmen:
$6.22B
Nettoeinkommen (Verlust:
$187.00M
KGV:
8.9588
EPS:
0.7166
Netto-Cashflow:
$508.00M
1W Leistung:
-6.53%
1M Leistung:
-16.50%
6M Leistung:
-39.76%
1J Leistung:
-58.84%
1-Tages-Spanne:
$6.385
$6.45
1-Wochen-Bereich:
$6.34
$6.98
52-Wochen-Spanne:
$6.18
$15.88
Organon Co Stock (OGN) Company Profile
Firmenname
Organon Co
Sektor
Telefon
551-430-6000
Adresse
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
6.404 | 1.70B | 6.22B | 187.00M | 508.00M | 0.7166 |
|
LLY
Lilly Eli Co
|
995.11 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.56 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
226.91 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
193.17 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
155.76 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Underweight |
| 2025-10-27 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Herabstufung | Goldman | Buy → Neutral |
| 2023-09-21 | Eingeleitet | Barclays | Overweight |
| 2023-03-16 | Eingeleitet | Raymond James | Outperform |
| 2022-10-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Eingeleitet | Piper Sandler | Neutral |
| 2021-09-01 | Eingeleitet | BofA Securities | Buy |
| 2021-07-22 | Eingeleitet | Citigroup | Buy |
| 2021-06-15 | Eingeleitet | JP Morgan | Neutral |
| 2021-06-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Organon Co Aktie (OGN) Neueste Nachrichten
Organon trades in red for seven straight sessions - MSN
(OGN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - Sahm
Organon rises after update on independent review - MSN
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Royce & Associates LP Trims Position in Organon & Co. $OGN - MarketBeat
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Organon & Co. Hits Day Low of $7.50 Amid Price Pressure - Markets Mojo
Organon (OGN) HR chief gets stock awards, withholds shares for taxes - Stock Titan
Organon & Co. (NYSE:OGN) Short Interest Up 21.9% in February - MarketBeat
Organon (OGN) CFO granted shares, withholds stock to pay taxes - Stock Titan
Organon (OGN) executive reports PSU share awards and tax withholding - Stock Titan
Organon (OGN) CIO logs stock awards and tax withholding share disposals - Stock Titan
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax - Stock Titan
Organon (NYSE: OGN) interim CEO reports stock awards and tax share offsets - Stock Titan
Can VTAMA’s Pediatric Sleep Data Nudge Organon (OGN) Toward a Stronger Dermatology-Led Growth Identity? - simplywall.st
Organon & Co. (OGN) Stock Analysis: Key Insights On Its 25.17% Potential Upside - DirectorsTalk Interviews
KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian Syndrome - marketscreener.com
KDventures meddelar att Organon har avbrutit utvecklingen av det tidigare portföljbolaget Forendos läkemedelskandidat mot PCOS - GlobeNewswire Inc.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages - MarketBeat
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic Dermatitis - Bitget
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest - Yahoo Finance
OGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Organon presents sleep improvement data for VTAMA cream in children By Investing.com - Investing.com Australia
Assessing Organon (OGN) Valuation After VTAMA Sleep Outcome Data From Phase 3 ADORING Trials - simplywall.st
Organon presents sleep improvement data for VTAMA cream in children - Investing.com
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN - MarketBeat
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Nigeria
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit - Sahm
Organon & Co. Confronts Mounting Global Pricing Pressure as Health Reforms Threaten Margin Stability and Nexplanon Growth - TipRanks
Organon & Co. (NYSE:OGN) Trading Down 6.3%Time to Sell? - MarketBeat
Organon & Co. (OGN) Stock Analysis: Navigating a Potential Upside Amidst a Challenging Landscape - DirectorsTalk Interviews
Decoding Organon & Co (OGN): A Strategic SWOT Insight - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Organon & Co. (NYSE:OGN) Price Target Raised to $8.00 at Barclays - MarketBeat
Organon price target raised to $8 from $7.50 at Barclays - TipRanks
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals By Investing.com - Investing.com India
Organon & Co. (OGN) posts FY adjusted EPS of $3.66, EBITDA margin at 30.7% - MSN
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% - Insider Monkey
Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus - TechStock²
Organon Signs Deal for Global Rights to Sebela's Miudella Intrauterine Device - marketscreener.com
Organon licenses hormone-free copper IUD from Sebela Pharmaceuticals - Investing.com
Organon Licenses MIUDELLA® to Enhance Women's Health Commitment - Intellectia AI
Organon enters into agreement to license Miudella® - marketscreener.com
First hormone-free copper IUD in 40 years lands $27.5M Organon deal - Stock Titan
Organon (OGN) Is Up 9.6% After Weaker 2025 Earnings And New 2026 Revenue GuidanceWhat's Changed - simplywall.st
Organon climbs 6% after audit clears company of wrongdoing - MSN
Organon Shares Rally as Investigation Clears Company of Wrongdoing - AD HOC NEWS
Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Up 6.6%What's Next? - MarketBeat
Finanzdaten der Organon Co-Aktie (OGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.59%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):